Cancer Genetics

Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.

The program enables NJ-based tech firms to sell net operating losses and R&D tax credits for at least 80 percent of the value of the tax benefits.

The test, which also is FDA-approved, can be used to identify best responders to three non-small cell lung cancer treatment regimens.

The company plans to offer 3.5 million units, comprising one share of common stock and one warrant to buy an additional share, at $2 per unit.

The partners will collaborate on educational and collaborative oncology clinical research activities in India to drive use of genomic technologies.

The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.

The firm missed analysts' expectations on both the top and bottom lines, despite a reported 20 percent increase in clinical services revenues during the quarter.